Absci Corporation
ABSIAbsci is a clinical-stage biopharmaceutical company that utilizes an AI-native approach to design and develop differentiated antibody therapeutics.
Earnings
Next report
Aug 11, 2026 (In 1 week)Valuation & ratios
Competitors
By market cap
By revenue growth
By net margin
Profile
Absci is a clinical-stage biopharmaceutical company that utilizes an AI-native approach to design and develop differentiated antibody therapeutics. The company leverages its proprietary Integrated Drug Creation platform, which combines generative AI models with a high-throughput 'lab-in-the-loop' system to accelerate the discovery of treatments for underexplored biological mechanisms. Its core value proposition lies in reducing the time and cost of drug development while targeting first-in-class or best-in-class positions in high-unmet-need indications.
A pioneer in generative AI for de novo antibody design, specifically targeting 'zero-prior' epitopes that lack known protein binders.
Questions, answered.
- What is Absci Corporation's market cap?
- Absci Corporation (ABSI) has a market capitalization of $1.3B and trades on NASDAQ.
- What is Absci Corporation's revenue and profitability?
- Absci Corporation generated $1.8M in trailing twelve-month revenue with a net loss of $118.4M, representing a net margin of -6450.8%, with free cash flow of -$98.5M. These figures are based on the Q1 2026 filing.
- Who are Absci Corporation's competitors?
- Absci Corporation's key competitors include Recursion Pharmaceuticals, Inc., Schrödinger, Inc., Spyre Therapeutics, and others. These companies compete in similar markets and product categories.
- Who does Absci Corporation partner with?
- Absci Corporation's notable partners include Merck, AstraZeneca, Almirall.
- Where is Absci Corporation headquartered?
- Absci Corporation is headquartered in United States of America and employs approximately 156 people. It has been publicly traded since 2021.
